

Key Information and Investment Disclosure Statement

As of May 31, 2023

FUND FACTS

Classification: Global Equity Feeder Fund

February 1, 2021 Launch Date: USD 1,000.00 **Minimum Investment:** USD 500.00 **Additional Investment:**

Minimum Holding Period: None

USD 86.31 **NAVPU:**

USD 6.45 Total Fund NAV (Mn): **Dealing Day:** Daily up to 1:30 PM

Redemption Settlement: T+5 End-of-Day

None

Early Redemption Charge:

FEES

Trustee Fees: Custodianship Fee: 0.00% 0.0850%

BPI Wealth None

*As a percentage of average daily NAV for the month valued at USD 6.65 Million

External Audit Fee: 0.00% Other Fees: 0.01%

Isla Lipana Index Licensing Fee

BPI Wealth

***Billings received in **Billing is received at the last quarter of the year June 2022

INVESTMENT OBJECTIVE AND STRATEGY

The Fund, operating as a Feeder Fund, intends to achieve for its Participants long term capital growth by investing in a Target Fund that invests in stocks in the health care sector. The Fund aims to provide excess return over the MSCI World Health Care Index. Pursuant to existing BSP rules and regulations, as a Feeder Fund, this Fund is mandated to invest at least 90% of its assets in a single collective investment scheme.

CLIENT SUITABILITY

A client profiling process shall be performed prior to participating in the Fund to guide the prospective investor if the Fund is suited to his/her investment objectives and risk tolerance. Clients are advised to read the Declaration of Trust/Plan Rules of the Fund, which may be obtained from the Trustee, before deciding to invest.

The BPI Invest Global Health Care Feeder Fund is for investors who:

- Are at least classified as aggressive based on their risk profile.
- Have an investment horizon of at least five (5) years.

Participation in the Fund shall be open to Participants with legal capacity to contract and who are not considered US persons under the US securities and tax laws, subject to the other conditions, rules or provisions stated in the Plan Rules and those established by the Trustee. No beneficial owner shall hold more than 10% of the Fund. Any investor who owns more than 10% shall be asked to redeem the amount (or its equivalent number of units) in excess of 10% within thirty (30) calendar days.

KEY RISKS AND RISK MANAGEMENT

You should not invest in this Fund if you do not understand or are not comfortable with the accompanying risks.

Market/Price Risk:

Investors are exposed to adverse changes in the prices of global equities in the health care sector due to adverse market conditions, unfavorable company earnings and valuations, and negative developments in the

political and economic conditions of the focus countries of the securities of the target fund.

Investors are exposed to the risk of loss due to the target fund's inability to convert security holdings to cash Liquidity Risk: immediately or in instances where conversion to cash is possible but at a highly disadvantageous price due to

limited participants in the market, low trading volumes, market disruptions, among others.

Investors are exposed to the risk of loss arising from negative developments in the political, economic and Country Risk: social conditions of the focus countries of the underlying securities of the target fund, which may adversely

affect the value of the feeder fund.

FX Risk:

Investors are exposed to the risk of loss from a decline in the market value of the target fund when the market value of foreign currency denominated securities held by the target fund are translated to USD.

The Fund's investment outlets undergo proper screening and evaluation in accordance with the Trustee's accreditation process. The Fund may also use financial derivatives to hedge the portfolio against market and credit risks.

- THE UIT FUND IS NOT A DEPOSIT AND IS NOT INSURED BY THE PHILIPPINE DEPOSIT INSURANCE CORP. (PDIC).
- RETURNS CANNOT BE GUARANTEED AND HISTORICAL NAVPU IS FOR ILLUSTRATION OF NAVPU MOVEMENTS/ FLUCTUATIONS ONLY.
- WHEN REDEEMING, THE PROCEEDS MAY BE WORTH LESS THAN THE ORIGINAL INVESTMENT AND ANY LOSSES SHALL BE SOLELY FOR THE ACCOUNT OF THE CLIENT.
- THE TRUSTEE IS NOT LIABLE FOR ANY LOSS UNLESS UPON WILLFUL DEFAULT, BAD FAITH OR GROSS **NEGLIGENCE.**
- •THIS PRODUCT CANNOT BE SOLD TO YOU UNLESS ITS BENEFITS AND RISKS HAVE BEEN THOROUGHLY EXPLAINED. IF YOU DO NOT FULLY UNDERSTAND THIS PRODUCT, DO NOT PURCHASE OR INVEST IN IT.

FUND PERFORMANCE AND STATISTICS AS OF MAY 31, 2023

(Purely for reference purposes and is not a guarantee of future results)

NAV	PU GRA	PH							
120		m.0	^		ia.				
110	- Person	W- W		WW	\A.	M.	al party	on the same	/m
100	~~~	~~~	Δ.		V	. 1	M		
90			~ /	MAN	١.,	M.	-44		~~
80				• • •	W	. N	W	*	
70		Fund		Benchm	nark*				
Mar-2	1 Jun-21	Sep-21	Dec-21	Mar-22	May-22	Aug-22	Nov-22	Feb-23	May-23

90				M	JAN PA	M.,	and the same	June .
80 70	_	Fund	_	-Benchr	nark*	•	_	
Mar-21	Jun-21	Sep-21	Dec	-21 Mar-22	May-22	Aug-22 N	lov-22 Feb-23	May-23
*MSC	l World H	Health Ca	are Ir	ndex				
CUMUL	_ATIVE	PERF	OR	MANCE	(%) ¹			
		1 r	no	3 mos	6 mos	1YR	3YRS	S.I. ²
Fund		-1.	83	3.03	-0.40	3.12	-	-13.69
Benchn			09		-1.74	-0.25	-	9.13
ANNUALIZED PERFORMANCE (%) 1								
		1\	/R	2YRS	3YRS	4YRS	S 5YR	S.I. ²
Fund			12		-	-	-	-6.13
Benchn			25		-	-	-	3.83
CALENDAR YEAR PERFORMANCE (%) 1								
			D					
Fund			<u>61</u>					
Benchn		-2.		-5.02	18.13			
PORTFOLIO COMPOSITION								
Allocation % of Fund								
Target Fund 98.78								
Cash and Equivalents 1.27								
Others – net of liabilities -0.04								
Regional Breakdown % of Target Fund								
United							72.2	
United		m					8.23	
Switzerland							4.8	
Others 14.64								
Sector Breakdown % of Target Fund								
Major Pharmaceuticals 26.07								
Biotechnology 17.99								

NAVPu over the past 12 months					
Highest	90.01				
Lowest	76.96				
STATISTICS					
Volatility, since inception (%) ⁴	17.21				
Sharpe Ratio ⁵	-0.04				
Information Ratio ⁶	0.20				
10.1					

- ¹ Returns are net of fees.
- ² Since Inception
- ³ Fund performance from Feb to year-end 2021
- ⁴ Measures the degree to which the Fund fluctuates vis-àvis its average return over a period of time
- ⁵ Used to characterize how well the return of a Fund compensates the investor for the level of risk taken. The higher the number, the better.
- ⁶ Measures reward-to-risk efficiency of the portfolio relative to the benchmark. The higher the number, the higher the reward per unit of risk.
- ⁷Effective March 1, 2022, transaction cut off times of the Fund have been temporarily adjusted until further notice. Announcements for changes of Fund cut off times shall be available on our website.
- *Declaration of Trust is available upon request through your branch of account.

TOP TEN HOLDINGS

Name	% of Target Fund
Eli Lilly & Co.	6.54
UnitedHealth Group Inc	6.40
AstraZeneca PLC	4.99
Merck & Co. Inc	4.92
Pfizer Inc.	4.00
Novartis AG	3.43
Danaher Corp.	2.93
Boston Scientific Corp	2.69
Daiichi Sankyo Co.	2.02
Illumina Inc	1 95

RELATED PARTY TRANSACTIONS*

The Fund has no transactions and outstanding investments with entities related to BPI Wealth – A Trust Corporation ("BPI Wealth").

* Related party in accordance with BPI Wealth's internal policy.

OTHER FUND FACTS

Health Services

Others

Medical Technology

Fund Currency: US Dollar Fund structure: UCITS (IRL)

Benchmark*: MSCI World Health Care Index **Inception Date:** October 31, 2003

15.57

12.87 27.50

Wellington Global Health Care Equity State Street Custodial Services Name of Target Fund: **Custodian:**

(Ireland) Limited

Regulator: Central Bank of Ireland **Total Expense Ratio:** 1.32%

Fund Manager: Wellington Management Company LLP

Fund

The Fund Performance Report and relevant information about the Wellington Global Health Care Equity Fund can be viewed and downloaded through https://www.wellingtonfunds.com/en-at/institutional/.

OUTLOOK AND STRATEGY

Market Review. Global equity markets modestly declined in May. Markets remained volatile throughout the month amid the US debt ceiling talks, raising concerns of a potential default. Despite the impasse on the US debt ceiling decision, the US Federal Reserve raised its interest rates by 25 basis points, pushing its policy rate above 5% for the first time since 2007, as inflation remained persistently elevated. The US Consumer Price Index marginally declined to 4.9% year-on-year in April from 5% in March, driven by lower energy prices. Across regional markets, returns were mixed as emerging market equities underperformed the broader equity indices due to Chinese equities selling off amid weaker economic data and slower business activity. On the positive side, Japanese equities rallied during the month driven by supportive monetary policy and bullish momentum on the economy. On a sectorial perspective, technology stocks rose as investor optimism on artificial intelligence provided a boost to the sector.

MSCI World Health Care Index returned -4.1% for the month. Within the index, health care services and biopharma large cap were the top performing sub-sectors.

Fund Performance. The fund returned -1.83% in May, above the benchmark by 226 basis points. Year-to-date, the fund returned, -1.61%, outperforming the benchmark by 112 bps. Strong selection within biopharmaceuticals helped performance.

Fund Strategy. Supportive valuations, robust innovation pipeline and business models that are positioned to show resilience through the cycle should benefit the sector over the long-term. Within the biopharma industry, the fundamental backdrop, resilient earnings and breakthrough innovations, particularly in disease areas and oncology, are expected to become tailwinds in a potential recessionary environment. Outside of biopharma, medical technology companies have numerous opportunities due to advancements in technology development, engineering capabilities, and integrated informatics. In the medium-term, many firms are expected to grow their addressable market through geographic expansion, new technologies, and new patient populations. The fund will continue to favor companies that develop innovative products designed to address important unmet medical needs. Over the long term, the tailwinds of innovation and an aging population should continue to drive growth for the sector.

LIST OF PROSPECTIVE INVESTMENTS

The following are among the Fund's approved investment outlets, wherein the Trustee intends to invest depending on strategy, availability, or other market-driven circumstances:

- (a) Primarily in a single collective investment scheme whose investment objective is to provide investment results in excess of the return of the MSCI World Health Care Index; provided further that such CIS is approved or registered and supervised by a regulatory authority that is a member of the International Organization of Securities Commissions (IOSCO) and managed by reputable fund manager/s; provided further that the investment in the said collective investment scheme should at least be ninety percent (90%) of the total assets of the Fund. The Target Fund must be recognized as a collective investment scheme in its home jurisdiction by a regulatory authority or any regulatory authority acceptable to the BSP to supervise this CIS.
- (b) Short-term tradable fixed-income instruments issued or guaranteed by the Philippine government or the BSP; tradable securities issued by the government of a foreign country, any political subdivision/agency of a foreign country or any supranational entity; tradable fixed-income instruments issued by foreign or local financial institutions or private corporations; exchange- listed securities; marketable instruments that are traded in an organized exchange; loans traded in an organized market; and, such other tradable investments outlets/ categories as the BSP may allow. Provided, that, a financial instrument is regarded as tradable if two-way prices are quoted, readily available or regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.
- (c) Short-term tradable fixed-income instruments issued, underwritten, or otherwise dealt by BPI and/or any of its subsidiaries, affiliates, their successors-in-interest or assignees, their directors, officers, stockholders, and related interest, and any of their trust and fund managed accounts, under such terms and conditions as the Trustee may deem to be in the best interest of the Fund; and, any such other instruments as may be allowed under BSP regulations. Investment with related interests shall be in accordance with Section 414-Q of the Manual of Regulations for Non-Bank Financial Institutions.
- (d) The principal investments of the Fund will be denominated in, but not limited to the U.S. Dollar. The target fund invests in securities denominated in other currencies.
- (e) Bank deposits or tradable debt instruments issued by the BSP.
- (f) Such other investments allowed under regulations issued by the BSP.

INVESTMENT OBJECTIVE OF TARGET FUND

The Wellington Global Health Care Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies. Although the Fund is not constructed relative to a benchmark, the MSCI World Health Care index will serve as a reference benchmark.

BPI Wealth is a subsidiary of the Bank of the Philippine Islands. For inquiries and comments, please send an email to bpiwealth@bpi.com.ph or call us at (632) 8580-2682.

BPI Wealth as Trustee/Investment Manager is regulated by the Bangko Sentral ng Pilipinas. https://www.bsp.gov.ph

For more information, you may contact us at (632) 8580-AMTC (2682), email us at bpiwealth@bpi.com.ph.